Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.

We studied telomere length in the peripheral blood leukocyte samples of a large group of patients with chronic myelogenous leukemia (CML) by Southern blot hybridization using the (TTAGGG)4 probe. The average telomere length expressed as the peak telomere repeat array (TRA) of the peripheral blood sa...

Full description

Bibliographic Details
Main Authors: Boultwood, J, Fidler, C, Shepherd, P, Watkins, F, Snowball, J, Haynes, S, Kusec, R, Gaiger, A, Littlewood, T, Peniket, A, Wainscoat, J
Format: Journal article
Language:English
Published: 1999
_version_ 1797101650172706816
author Boultwood, J
Fidler, C
Shepherd, P
Watkins, F
Snowball, J
Haynes, S
Kusec, R
Gaiger, A
Littlewood, T
Peniket, A
Wainscoat, J
author_facet Boultwood, J
Fidler, C
Shepherd, P
Watkins, F
Snowball, J
Haynes, S
Kusec, R
Gaiger, A
Littlewood, T
Peniket, A
Wainscoat, J
author_sort Boultwood, J
collection OXFORD
description We studied telomere length in the peripheral blood leukocyte samples of a large group of patients with chronic myelogenous leukemia (CML) by Southern blot hybridization using the (TTAGGG)4 probe. The average telomere length expressed as the peak telomere repeat array (TRA) of the peripheral blood samples obtained from a group of 34 healthy age-matched controls ranged between 7.6 and 10.0 kb and the mean peak TRA was 8.7 kb. Forty-one patients in the chronic phase of CML were studied; 32/41 (78%) showed telomere reduction (<7.6 kb) relative to age-matched controls and the mean peak TRA was 6.4 kb (range 4.0-10.6 kb). Serial samples were analysed from 12 patients at both chronic phase and during disease progression. The leukocyte DNA of all 12 patients in accelerated phase and/or blast crisis showed telomere reduction relative to age-matched controls and the mean peak TRA was 4.1 kb (range 3.0-5.4 kb). The peak TRA in the accelerated or blast phase was reduced compared with the corresponding paired sample in the chronic phase in all cases studied. These data show that a marked reduction in telomere length is associated with disease progression in CML.
first_indexed 2024-03-07T05:54:48Z
format Journal article
id oxford-uuid:ea2b5518-dbb4-4157-adc2-61ab73f8bc59
institution University of Oxford
language English
last_indexed 2024-03-07T05:54:48Z
publishDate 1999
record_format dspace
spelling oxford-uuid:ea2b5518-dbb4-4157-adc2-61ab73f8bc592022-03-27T10:59:38ZTelomere length shortening is associated with disease evolution in chronic myelogenous leukemia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ea2b5518-dbb4-4157-adc2-61ab73f8bc59EnglishSymplectic Elements at Oxford1999Boultwood, JFidler, CShepherd, PWatkins, FSnowball, JHaynes, SKusec, RGaiger, ALittlewood, TPeniket, AWainscoat, JWe studied telomere length in the peripheral blood leukocyte samples of a large group of patients with chronic myelogenous leukemia (CML) by Southern blot hybridization using the (TTAGGG)4 probe. The average telomere length expressed as the peak telomere repeat array (TRA) of the peripheral blood samples obtained from a group of 34 healthy age-matched controls ranged between 7.6 and 10.0 kb and the mean peak TRA was 8.7 kb. Forty-one patients in the chronic phase of CML were studied; 32/41 (78%) showed telomere reduction (<7.6 kb) relative to age-matched controls and the mean peak TRA was 6.4 kb (range 4.0-10.6 kb). Serial samples were analysed from 12 patients at both chronic phase and during disease progression. The leukocyte DNA of all 12 patients in accelerated phase and/or blast crisis showed telomere reduction relative to age-matched controls and the mean peak TRA was 4.1 kb (range 3.0-5.4 kb). The peak TRA in the accelerated or blast phase was reduced compared with the corresponding paired sample in the chronic phase in all cases studied. These data show that a marked reduction in telomere length is associated with disease progression in CML.
spellingShingle Boultwood, J
Fidler, C
Shepherd, P
Watkins, F
Snowball, J
Haynes, S
Kusec, R
Gaiger, A
Littlewood, T
Peniket, A
Wainscoat, J
Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.
title Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.
title_full Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.
title_fullStr Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.
title_full_unstemmed Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.
title_short Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.
title_sort telomere length shortening is associated with disease evolution in chronic myelogenous leukemia
work_keys_str_mv AT boultwoodj telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT fidlerc telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT shepherdp telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT watkinsf telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT snowballj telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT hayness telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT kusecr telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT gaigera telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT littlewoodt telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT peniketa telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia
AT wainscoatj telomerelengthshorteningisassociatedwithdiseaseevolutioninchronicmyelogenousleukemia